- Report
- November 2026
- 166 Pages
Global
From €5512EUR$5,850USD£4,589GBP
- Report
- November 2026
- 245 Pages
Global
From €5512EUR$5,850USD£4,589GBP
- Report
- November 2026
- 373 Pages
Global
From €5512EUR$5,850USD£4,589GBP
- Report
- November 2026
- 220 Pages
Global
From €5512EUR$5,850USD£4,589GBP
- Report
- November 2026
- 244 Pages
Global
From €5512EUR$5,850USD£4,589GBP
- Report
- November 2026
- 324 Pages
Global
From €5512EUR$5,850USD£4,589GBP
- Report
- November 2026
- 212 Pages
Global
From €5512EUR$5,850USD£4,589GBP
- Report
- November 2026
- 122 Pages
Global
From €5512EUR$5,850USD£4,589GBP
- Report
- November 2026
- 412 Pages
Global
From €5512EUR$5,850USD£4,589GBP
- Report
- November 2026
- 217 Pages
Global
From €5512EUR$5,850USD£4,589GBP
- Report
- November 2026
- 246 Pages
Global
From €5512EUR$5,850USD£4,589GBP
- Report
- November 2026
- 234 Pages
Global
From €5512EUR$5,850USD£4,589GBP
- Report
- November 2026
- 394 Pages
Global
From €5512EUR$5,850USD£4,589GBP
- Report
- August 2026
- 110 Pages
Global
From €4475EUR$4,750USD£3,726GBP
- Report
- August 2026
- 148 Pages
Global
From €4475EUR$4,750USD£3,726GBP
- Report
- August 2026
- 115 Pages
Global
From €4475EUR$4,750USD£3,726GBP
- Report
- August 2026
- 120 Pages
Global
From €4475EUR$4,750USD£3,726GBP
- Report
- August 2026
- 130 Pages
Global
From €4475EUR$4,750USD£3,726GBP
- Report
- August 2026
- 120 Pages
Global
From €4475EUR$4,750USD£3,726GBP
- Report
- August 2026
- 187 Pages
Global
From €4475EUR$4,750USD£3,726GBP

The Biosimilar market is a subset of the biotechnology industry that focuses on the development and production of biologic drugs that are similar to existing biologic drugs. Biosimilars are created using a process called recombinant DNA technology, which involves the manipulation of genetic material to create a drug that is similar to an existing biologic drug. Biosimilars are typically used to treat chronic conditions such as cancer, rheumatoid arthritis, and multiple sclerosis. Biosimilars are typically cheaper than their brand-name counterparts, making them an attractive option for patients and healthcare providers.
Some companies in the Biosimilar market include Amgen, Biocon, Celltrion, Dr. Reddy's Laboratories, Mylan, Pfizer, Sandoz, and Teva Pharmaceuticals. Show Less Read more